Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;40 Suppl 2(Suppl 2):S160-3.
doi: 10.1093/schbul/sbt143.

William T. Carpenter Jr: 35 years of clinical trials

Robert W Buchanan  1
Affiliations

William T. Carpenter Jr: 35 years of clinical trials

Robert W Buchanan. Schizophr Bull. 2014 Mar.

Abstract

William T. Carpenter Jr has had a major impact on the design and conduct of clinical trials in schizophrenia. His contributions range from the decisive evaluation of the efficacy of hemodialysis to the development of novel approaches to evaluate new treatments for cognitive impairments and negative symptoms. He has developed innovative dosage reduction strategies. He has led efforts to focus drug development on those illness components that are not responsive to antipsychotic treatment. He has emphasized throughout his career the use of translational science to provide the conceptual framework for clinical trial interventions. This article reviews highlights of his many contributions, with an emphasis on 3 areas: (1) dosage reduction studies; (2) the use of the domains of psychopathology to identify drug development targets; and (3) the use of translational science to guide new drug development.

Keywords: animal models; antipsychotics; cognitive impairments; negative symptoms.

PubMed Disclaimer

References

    1. Carpenter WT, Jr, Sadler JH, Light PD, et al. The therapeutic efficacy of hemodialysis in schizophrenia. N Engl J Med. 1983;308:669–675 - PubMed
    1. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull. 1995;21:567–577 . - PubMed
    1. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893–896 - PubMed
    1. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry. 1987;44:518–521 - PubMed
    1. Heinrichs DW, Carpenter WT., Jr Prospective study of prodromal symptoms in schizophrenic relapse. Am J Psychiatry. 1985;142:371–373 - PubMed

MeSH terms

Personal name as subject